前药
化学
胰高血糖素
低血糖
精氨酸
胰岛素
肽
组合化学
药理学
体外
聚乙二醇化
药品
溶解度
生物化学
产量(工程)
体内
中国仓鼠卵巢细胞
苯硼酸
毒品携带者
寡肽
生物活性
受体
功能(生物学)
高胰岛素血症
结合
赖氨酸
作者
Emily L. DeWolf,Weike Chen,Bernice Webber,Elizabeth M. Power,Rory Kilmer,Pradeep Kadu,Sijie Xian,Matthew J. Webber
出处
期刊:Small science
[Wiley]
日期:2026-03-01
卷期号:6 (3): e202500555-e202500555
被引量:2
标识
DOI:10.1002/smsc.202500555
摘要
Activatable prodrug strategies offer powerful means to control therapeutic presentation in space and time. Here, we report a single-molecule prodrug design that enables glucose-responsive activation of a glucagon analog for hypoglycemia protection. The system conjugates dasiglucagon with a synthetic pendant comprised of alternating arginine and phenylboronic acid (PBA) units, designed to couple peptide solubility to glucose concentration. The pendant modulates net charge through glucose-dependent PBA-diol complexation, driving aggregation under normoglycemia and solubilization under hypoglycemia. The lead pendant contains five arginine-PBA repeats and exhibits optimal glucose-responsive solubility and charge modulation, forming aggregates at high glucose and dissolving as glucose levels decline. Despite a modest reduction in receptor potency relative to native dasiglucagon, this approach provides significant prophylactic protection in a streptozotocin-induced diabetic mouse model of insulin overdose, rescuing mice from hypoglycemia and eliminating mortality events. This work demonstrates a proof-of-concept for molecularly engineered, metabolite-responsive glucagon prodrugs that function as on-demand therapeutic depots. More broadly, it establishes a modular design paradigm for dynamic, self-regulating peptide therapeutics based on charge modulation rather than external carrier systems.
科研通智能强力驱动
Strongly Powered by AbleSci AI